Targets › GH1
4 programs from 4 companies in 7 trials: 4 Phase 3, 3 Phase 2; Other, Metabolic and endocrine; next expected readout Dec 2026.
Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. (UniProt, P01241)
Open in Phaseline: the race on GH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Xiamen Amoytop Biotech | Inpegsomatropin Injection Pegylated recombinant human growth hormone (long-acting GH analog) | GH1 | Phase 3 | Small for Gestational Age; Turner Syndrome; Idiopathic Short Stature; Adult Growth Hormone Deficiency | Dec 2027 |
| Kexing Biopharm | GB06 Recombinant human growth hormone (biosimilar) | GH1 | Phase 3 | Growth Hormone Deficiency (GHD) | Jul 2028 |
| Changchun GeneScience Pharmaceutical | PEG-rhGH Injection (Jintrolong®) Recombinant human growth hormone with polyethylene glycol modification for extended half-l | GH1 | Phase 2 | Short Stature Children Born Small for Gestational Age (SGA) | Dec 2026 |
| Intervene Immune | TRIIM Treatment Combination of somatropin (recombinant human growth hormone), metformin, and DHEA | GH1, AMPK | Phase 2 | Epigenetic Aging | – |
Growth Hormone Deficiency (GHD) (1) Small for Gestational Age (1) Turner Syndrome (1) Idiopathic Short Stature (1) Adult Growth Hormone Deficiency (1) Short Stature Children Born Small for Gestational Age (SGA) (1) Epigenetic Aging (1)
small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.